What Gets Measured Gets Done

We set standards and benchmark the performance of pharma companies and new drugs on how the drugs are tested, marketed, and made available to patients.

So far, we have publicly launched our benchmarks on clinical trial transparency and data-sharing.  Why go to the trouble? Because clinical trials contain all the safety and efficacy information for new medicines and vaccines. And, before Bioethics International, no one organization consistently reviewed clinical trials to ensure they were publicly available in accordance with ethics and legal requirements.

We help ensure that clinical trial participants’ involvement is not wasted, but advances scientific knowledge. To date, we’ve assessed the transparency of thousands of clinical trials, enrolling over 528,683 patients and clinical trial participants around the world.

We make sure that the medical evidence for new drugs is publicly available, so doctors can prescribe the right drug for the right patient. This affects a large proportion of the US population, as in the past 30 days:

49% of people have used at least one prescription drug

On average, people age 45 and older say they take 4 prescription medications daily

When we reviewed medicines and vaccines for HIV, TB, breast cancer, rare diseases, pediatric meningitis, and many other conditions, approved by the FDA in 2012, we noticed there was room for improved transparency. We found:

35% of trial results per drug were publicly unavailable

1/2of all drugs had undisclosed results for their phase 2 or 3 trials

20%of large companies (2 in 10) disclosed all trial results

We realized low transparency may be contributing to the lack of trust in pharma companies and that distrust can create barriers for patients to participate in trials and take their medicines and vaccines. The percentage of Americans who trust that pharma companies are honest & ethical has been decreasing, year by year:

That’s why we published the First Good Pharma Scorecard in 2015— to focus on the ethical issues impacting patients the most and to rebuild patient-centricity and trustworthiness in healthcare innovation.  Our 2nd Good Pharma Scorecard, published in 2017 benchmarking drugs approved by the FDA in 2014, already shows meaningful progress has been made:

The proportion of new drugs with undisclosed phase 2 or 3 trials has gone down from

2015 50%

  Right arrow

2017 30%

The public availability of results for trials conducted in patients, for each drug, went up from

2015 87%

  Right arrow

2017 96%

The overall industry scores went up from a median of

2015 88%

  Right arrow

2017 91%